Recent advancements in radiation therapy, however, are providing new hope for extending patient survival and enhancing quality of life.
Recent advancements in radiation therapy, however, are providing new hope for extending patient survival and enhancing quality of life.
VORANIGO is the first FDA-approved targeted treatment in Grade 2 IDH-mutant glioma.
(Courtesy of ASCO FDA Alerts) tovorafenib FDA Approval for LGG On April 23, 2024, the Food and Drug Administration granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. […]
Modern radiation therapy for brain tumors, marked by precision, personalization, safety, and ongoing innovation, holds promise for enhancing patient outcomes and instilling hope in challenging diagnoses.
To truly support your loved ones during their times of need, consider these practical ways to provide help and show your support.
Shuttle Pharmaceuticals has submitted a new drug for FDA approval to improve the effectiveness of radiation therapy for GBM patients.
Oncoheroes Biosciences, Inc. has received the FDA's greenlight to proceed with two crucial clinical trials, which open the door to new drug treatments for pediatric cancer .
186RNL, a rhenium isotope, is studied as a treatment for recurrent glioma. Patients are currently being enrolled in clinical trials.
The Loc3CAR clinical trial is an exciting development in the treatment of pediatric primary central nervous system (CNS) neoplasms.
The FDA expanded use of Temodar to include two new indications for the treatment of adults with anaplastic astrocytoma.
